Muscles naturally become weaker as we get older, but scientists have discovered that some of the physiological changes traditionally associated with aging may actually serve a vital protective purpose, helping muscle cells defend themselves against cellular damage. New research sheds light on why aging muscles shift toward a distinct type of muscle fiber and identifies a crucial molecule that could ultimately offer an entirely new therapeutic approach to treating age-related muscle loss and associated wasting conditions.
To understand this biological puzzle, researchers look closely at how muscle tissue is constructed. Muscle tissue contains intricate bundles of fibers that serve different functions depending on the physical demands placed upon them. Fast-twitch fibers are built to produce powerful, rapid movements, but they fatigue relatively quickly under sustained exertion. Slow-twitch fibers, by contrast, are specialized to support sustained, endurance-based activity. Crucially, these slow-twitch fibers contain significantly higher concentrations of mitochondria, which are the specialized cellular structures responsible for producing the vast majority of the chemical energy that muscles need to operate.
As people age, however, overall muscle strength steadily declines and these vital mitochondria become progressively less efficient at generating energy. Surprisingly, despite this energetic decline, aging muscles simultaneously develop a greater proportion of slow-twitch fibers. This shift occurs even though slow-twitch fibers depend heavily on the very mitochondria that are losing their ability to function properly. Researchers have noted similar paradoxical shifts in several clinical conditions that cause severe muscle wasting, leaving scientists wondering why the body would push aging muscles to increasingly rely on an energy-producing system that is steadily becoming less effective.
A Crucial Molecule Linked to Muscle Aging
To investigate this deep biological mystery, an international team of scientists focused their attention on cardiolipin, a specialized and complex fat molecule located almost exclusively within the inner membrane of mitochondria. Cardiolipin plays a fundamental physiological role by helping maintain the membrane’s distinctive folded architecture, which is an absolute prerequisite for proper mitochondrial activity and efficient energy production.
When cardiolipin is lacking or depleted, mitochondria struggle intensely to generate sufficient energy to meet cellular demands. Furthermore, these compromised structures become significantly less capable of producing the essential chemical signals and building blocks that cells require to function normally. Through their investigations, the researchers discovered that cardiolipin levels decline significantly in muscle mitochondria derived from both mice and humans as they age or experience disease-related wasting. This notable chemical decline was consistently accompanied by pronounced structural abnormalities within the mitochondria and a total loss of normal metabolic function.
To determine whether reduced cardiolipin directly contributes to these detrimental cellular changes—rather than merely occurring alongside them as an innocent bystander—the research team experimentally lowered cardiolipin levels in young, healthy mice. The results of this intervention closely mirrored what typically happens during natural aging. Muscle fibers shifted away from the fast-twitch type toward slow-twitch fibers, matching the exact pattern that had been previously observed in older mice and human tissue samples.
Even more strikingly, when the researchers restored cardiolipin concentrations to approximately two-thirds of their normal, healthy levels, the intervention began reversing the progression of muscle wasting. Remarkably, it also completely prevented the premature deaths observed in the affected animal models, pointing to a profound link between cardiolipin availability and overall muscular health.
Why Aging Muscles Sacrifice Strength for Protection
Further rounds of laboratory experiments revealed an unexpected and counterintuitive explanation for this cellular transformation. Rather than representing a simple breakdown or failure in muscle function, the progressive shift toward slow-twitch fibers appears to act as a calculated, protective response orchestrated by the tissue itself.
When cardiolipin concentrations fall below optimal thresholds, damaged mitochondria begin producing much larger quantities of reactive oxygen species, commonly known as ROS. While these highly unstable, reactive molecules have the potential to inflict serious harm on surrounding cellular structures, they also play a critically important signaling role, alerting the cell that something is fundamentally wrong with its metabolic machinery.
The researchers discovered that these elevated levels of reactive oxygen species help initiate and drive the transition from fast-twitch to slow-twitch muscle fibers. To test this mechanism, when they treated muscle cells lacking cardiolipin with an antioxidant designed to mop up and reduce ROS, the characteristic transformation between fiber types became significantly less pronounced.
A specialized protein known as ERRγ plays a central role in coordinating this intricate cellular response. This protein directs cells to systematically reorganize their mitochondria and alter their overall muscle fiber characteristics in response to stress. When scientists experimentally inhibited ERRγ in muscle cells grown in the laboratory, the transition between muscle fiber types stopped entirely, confirming the protein’s indispensable role in the adaptation process.
The research team also uncovered how these newly remodeled slow-twitch fibers help defend themselves against ongoing cellular stress. Mice with insufficient cardiolipin absorbed considerably more glucose directly from their bloodstreams than normal mice did. However, detailed tracking experiments using specially labeled glucose revealed that their muscles were not primarily utilizing this additional sugar to produce energy.
Instead, the muscle cells redirected the incoming sugar toward manufacturing their own internal antioxidants. This metabolic redirection helped protect the vulnerable tissue against the damaging effects of excess reactive oxygen species generated by struggling mitochondria.
"The fiber switch is not the muscle failing, but the muscle trading power for protection. That’s also why interfering with it can backfire: when we gave the mice antioxidants to mop up the ROS, their muscles fared worse, not better," explained Assistant Professor Fabian Finger, who served as the first and co-corresponding author of the study from the University of Copenhagen.
A Potential New Approach to Treating Muscle Wasting
Although these groundbreaking findings point toward possible future treatments for age-related muscle decline, the experiments demonstrating the protective mechanism and the subsequent reversal of muscle wasting were conducted primarily in mice. Human muscle samples were utilized in the study specifically to establish that cardiolipin levels do indeed decrease with age in people, grounding the animal findings in human relevance.
Nevertheless, researchers already have some practical avenues available to influence cardiolipin levels in a medical context. The U.S. Food and Drug Administration recently granted accelerated approval to elamipretide, a specialized medication designed to help stabilize cardiolipin, for the treatment of Barth syndrome, a rare and debilitating inherited disorder. This regulatory milestone suggests that targeting the cardiolipin molecule directly is medically feasible, although its specific efficacy against ordinary, age-related muscle loss remains to be thoroughly tested in clinical trials.
Another potential therapeutic target identified by the team is ERRγ, the protein responsible for helping muscles adapt to severe mitochondrial stress. ERRγ belongs to a prominent family of proteins called nuclear receptors. These receptors are already well-established targets for approximately 10 to 15 percent of all FDA-approved medications derived from small molecules. Furthermore, experimental drugs designed to activate ERRγ are already being actively investigated in preclinical research for various other medical applications.
Taken together, the findings suggest that future therapeutic strategies might operate either by restoring depleted cardiolipin levels directly or by intelligently influencing the protective cellular adaptations controlled by ERRγ.
"What encourages me most is that even a partial recovery of cardiolipin was enough to bring the muscle back. The question now is whether we can increase cardiolipin in aging muscle or target ERRγ to promote healthy adaptations. This is where the therapeutic potential lies," said senior author Zachary Gerhart-Hines, an Associate Professor at the NNF Center for Basic Metabolic Research at the University of Copenhagen.
The extensive research effort involved collaborating scientists from more than 20 distinct institutions. It was led principally by the NNF Center for Basic Metabolic Research at the University of Copenhagen in close partnership with the Center for Adipocyte Signaling at the University of Southern Denmark. Financial support for the project was provided by the Novo Nordisk Foundation, the European Research Council, the Lundbeck Foundation, the U.S. National Institutes of Health, and several other funding organizations.